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Abstract
               The   understanding   of   the   mechanisms   of   action   and   side  effects   of   different 
antiarrhythmic drugs (AAD) are essential for their appropriate use. With the advent of effective 
and safe ablation therapy, AAD therapy has undergone dramatic changes. This review attempts 
to understand the rationale behind the clinical use of medical management of different 
arrhythmias.  
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Introduction
            With the market share of drug use in Pediatric population being relatively small, drug 
companies have little incentive for drug trials. The use of AADs in children is often off label and 
derived from the adult experience. The efficacy of arrhythmia control in children may vary 
considerably. It is important to understand the following definitions:                                          
Pharmacokinetics:  It is the study of drug concentrations after oral or intravenous (IV) 
administration
Pharmacodynamics: It is the study of the variability in the response to the drug concentrations.  
Pharmacogenetics:  It is the study of inherited variability in response to drug therapy.         
Bioavailabilty:  It is the amount of drug reaching the systemic circulation usually after oral 
administration as compared to IV therapy. Bioavailabilty depends on 1) Drug absorption 2) 
Metabolism before reaching systemic circulation (such as hepatic or enteral metabolism).           
Steady state: State at which the amount of drug leaving the plasma and tissues equals the amount 
entering the plasma and tissues after chronic drug administration.                              
Elimination half life: Time required for the plasma concentration to fall by 50%. In 2 half lives 
75% of the drug is eliminated, in 3 half lives 87.5% and almost complete elimination in 5-6 half 
lives.
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            Drug elimination is defined as a "first order" process if the rate at which the drug is 
eliminated depends on the plasma concentration. A "zero order" process is when the drug is 
eliminated per unit time regardless of the drug concentration e.g. Ethanol.                           
Clearance: It is the amount of drug cleared by metabolism per unit time. Factors that affect 
clearance include organ dysfunction and concomitant drug therapy that affect metabolism. Rapid 
clearance of drugs such as esmelol reflects activity of plasma esterases1 whereas the clearance of 
adenosine is due to widespread drug uptake into intracellular sites (RBCs)2.                     
Volume of distribution: The central volume of distribution is the volume into which the IV 
bolus distributes. Dose adjustment may be required in situations of altered volume of distribution 
such as congestive heart failure. The half life of a drug is directly proportional to the volume of 
distribution and inversely proportional to the clearance.                                                                 
               Drug clearance may be reduced by 1) Dysfunction of the eliminating organ, 2) 
Concomitant drug therapy that inhibits metabolic or transport pathway, 3) Defective function of 
drug   eliminating   protein.                                                                                      
            It is a common misconception that drug need to administered once per half life. Optimum 
dosing is determined not only by drug's elimination rate but also by the margin between the 
minimally effective and maximally tolerated plasma concentration.                                             
Classification and mechanism of action Antiarrhythmic Drugs                              
            The modified Singh-Vaughan Williams classification3 is as follows:                           
Class   I   agents                                                                                            
Class   I   A                                                                                                  
            These reduce the conduction velocity and prolong repolarization thus prolonging action 
potential duration. These include Quinidine, Procainamide and Disopyramide                     
Quinidine:  It is derived  from the bark of cinchona tree and delays  depolarization  and 
repolarization by Na channel4  and IKi channel blocking effects respectively. It can cross 
placenta and gets excreted in breast milk. It is effective in atrial arrhythmias such as atrial flutter 
and fibrillation, re-entry SVTs and ventricular arrhythmias such as VT. Use of quinidine has 
declined because of potent side effects such as diarrhea, abdominal cramping, thrombocytopenia, 
hemolytic anemia, decreased hearing and tinnitus, QRS widening and proarrhythmia5. Dosage 
used   is   30-60mg/kg/day   in   four   divided   doses.                                                    
Procainamide: It prolongs action potential duration (APD) by sodium channel blocking effect. It 
is metabolized to N-acetyl procainamide (NAPA) that has class III effects. Some additional 
effects include alpha adrenergic blocking (decreased sympathetic efferent activity) that may 
cause hypotension and vagolytic action that may increase the AV node response of atrial 
arrhythmias such as atrial flutter and fibrillation. It crosses placenta and is excreted in breast 
milk.  It is effective in a wide range of atrial and ventricular arrhythmias. The intravenous form 
is often used as first line of therapy in postoperative (after CHD repair) atrial and ventricular 
arrhythmias. Side effects include hypotension, GI side effects, drug induced lupus6, hemolytic 
anemia and rarely proarrhythmia. Oral dosing is 40-100 mg/kg/day in 4-6 divided doses. IV 
loading is done with 5-15mg/kg followed by 40-100 mcg/kg/min. Procainamide/NAPA levels 
are helpful in monitoring therapy especially in slow acetylators (10-40% of the population)
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Disopyramide: This has similar action as quinidine without the adrenergic effects. It is effective 
in refractory vasodepressor syncope7. The negative inotropic effect inhibits the ventricle from 
becoming hypercontractile which is the trigger for the vasodepressor reflex. The dose used is 
20-30 mg/kg/day in 3-4 divided doses. Side effects include anticholinergic effects such as 
urinary retention, constipation blurred vision and dry mouth. Renal clearance may be affected by 
betablockers.  
Class   I   B                                                                                                
            These drugs shorten APD and repolarization by bocking the fast Na channel activity and 
include lidocaine, mexilitine, phenytoin, tocainide and moricizine.                              
Lidocaine: Most of the effects are below the His bundle and results in overall homogeneity of 
the ventricular muscle repolarization. It has an extensive first pass hepatic metabolism with a 
rapid distribution phase. It has poor oral absorption and it does cross the placenta. It is effective 
in acute management of VT especially torsades (Figure 1). IV dosing is 1-4 mg/kg bolus 
followed by infusions of 20-50mcg/kg/min. Side effects include CNS symptoms such as 
numbness, altered sensorium, seizures and apnea.
Figure 1: EKG of a 6 yr old with recurrent episodes of syncope showing torsades who successfully treated with IV 
Lidocaine. 
Mexilitine:  This is an oral form of lidocaine with similar Na channel effects. It is rapidly 
absorbed from the GI tract with extensive hepatic metabolism. It is effective in chronic therapy 
of some VTs and also LQTS (type III)8. It is known to cross the placenta and has been used on 
some case of fetal ventricular arrhythmias from congenital prolongation of the QT interval. 
Dosing range is 2-8 mg/kg/day in 3 divided doses. Side effects include skin rash and GI 
intolerance.  
Phenytoin:  It has similar effects as Lidocaine on the Na channel but also has Ca channel 
blocking and sinus node and AV node effects in higher concentrations. Its effect of depressing 
phase 4 depolarization is used in treatment  of digoxin  toxicity. It  is  used  in   some   forms   of 
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refractory ventricular arrhythmias. It crosses the placental barrier and is know to have a potent 
fetal teratogenic effect. Maintenance dosing is 3-6 mg/kg day in 2 divided doses after an initial 
loading   of   10-15   mg/kg.   Side   effects   include   hypotension,   nystagmus,   ataxia,   gingival 
hyperplasia, skin rash (may progress to Steven Johnson's syndrome) and fetal hydantoin 
syndrome (cleft lip/palate, microcephaly, mental retardation, finger/nail hypoplasia and CHD) if 
used   in   pregnancy.                                                                        
Class   IC                                                                                
            These agents are potent in blocking Na and affecting repolarization. They also have an 
effect on inward K channel (iK) and the slow inward Ca (iCa) current. They include flecanide, 
propafenone   and   encanide.                                                                          
Flecanide: It prolongs ventricular APD and refractory periods leading to QRS prolongation. In 
the specialized conduction tissue, it shortens the refractory period and decreases automaticity. It 
crosses the placenta effectively (upto 70% of maternal levels) and can be used in fetal 
arrhythmias. In the pediatric population, it has been used in a wide variety of arrhythmias 
including re-entry SVT, EAT, IART and some forms of VTs9. Its use in the presence structural 
heart disease (ischemic heart disease and CHD) has been questioned by CAST study10.  Dosing 
is 80-180mg/m2/day in 2-3 divided doses. Flecanide levels can be used to monitor therapy and 
toxicity. Side effects include blurry vision, prolongation of the QRS duration and proarrhythmia 
especially in the presence of structural heart disease.                                                        
Propafenone: Effects are similar to flecanide and also has mild betablocking effects, and some 
effects on the slow inward Ca current and delayed outward potassium current. It is effective in 
especially automatic atrial tachycardia11. It is extensively metabolized in liver. Oral dosing is 
150-500 mg/m2 in 3-4 divided doses. Side effects include blurry vision, lupus like syndrome and 
conduction system disturbances including bundle branch blocks.                                
Class   II   drugs                                                                                
            These are agents with beta adrenergic blocking properties. These include beta-1 (cardiac) 
selective (atenelol, metoprolol), non selective (propranolol, nadalol) and drugs that have intrinsic 
sympathomimetic   activity  (ISA)  (Pindalol)                                                                
Propranolol: It is the most commonly used betablocker which has membrane effects on the Na 
channel and weak Ca channel effects with higher doses. It has little effect on the APD but 
prolongs   intranodal   conduction   (increases   AH  interval   and   Wenckebach   block).   Hepatic 
metabolism and clearance is extensive. It crosses the placenta easily and fetal hypoglycemia is a 
concern with maternal use. It is widely used as first choice in re-entry SVT of all ages (including 
newborns), some ventricular arrhythmias (especially catecholamine sensitive) and is also the 
drug of choice in LQTS (Figure 2). It blunts the imbalance between the sympathetic and 
parasympathetic influence and hence heterogeneity of the ventricular muscle refractoriness in 
post MI patients and hence improves survival. Dosing is between 1-4 mg/kg per day in 3-4 
divided doses. Co-administration with Ca channel blockers may cause synergistic negative 
inotropic  effect on  contractility.   Side  effects  include  bradycardia,  hypotension12, fatigue, 
depression and may exacerbate bronchospasm.
Atenelol: It is another commonly used long acting betablocker that has selective beta-1 effects 
and does not cross the blood brain barrier. It is used in re-entry SVTs and ventricular 
tachycardia13 in older children with convenience of once or twice a day dosing. Oral dosing is 
1-2 mg/kg per day. Side effects are similar to propranolol but less common.                           
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8 (3): 202-210 (2008)V. Ramesh Iyer, “Drug Therapy Considerations in Arrhythmias in Children”                    206
Figure 2: EKG of a 2 month old girl with LQTS (QTC of 520ms.) who was treated with propranolol.
Nadalol: It is a non selective betablocker with similar actions as propranolol but has a longer 
half life. It is used in reentry SVT14 and autonomic syndromes (vasodepressor syncope). Oral 
dosing is 1-2 mg/kg per day in 1-2 divided doses.                                                                           
Esmolol: It is an IV form of cardioselective betablocker that has half life of only 7-10 mins. The 
predominant sites of action are the sinus and AV nodes. It is used in the acute treatment of re-
entry SVTs and catecholamine sensitive VTs15 and also rate control of non-reentry tachycardia 
such as atrial flutter and EAT. IV dosing is 500 mcg/kg bolus over 1-2 mins followed by an 
infusion of 50-200 mcg/kg/min. Side effects include hypotension and bradycardia.                  
            Other betablockers that have not been used frequently in children include Pindalol and 
Carvedilol. Pindolol has potent ISA and may be used in arrhythmia control in patients with sinus 
or AV node disease as it doesn't cause much bradycardia. Carvedilol has additional vasodilator 
and antioxidant properties and improves ventricular function which has made it use popular in 
chronic   CHF.                                                                                                    
Class   III   drugs                                                                                            
 
        These agents effect the membrane repolarization and thus prolong the APD and refractory 
period. The drugs have predominant K channel effects with some Na and Ca channel blocking 
properties. Higher doses also have beta and alpha adrenergic blockade contributing to its 
therapeutic actions. These result in reduction in membrane excitability of all myocardial tissue. 
Amiodarone, Sotalol, Ibutalide and dofetalide belong to this class.                             
Amiodarone: It is considered to be one of the most effective antiarrhythmic agents even in the 
presence of CHD and heart failure. It is effective in a variety of reentry SVTs, atrial flutter and 
fibrillation, automatic EATs and life threatening ventricular arrhythmias16. Oral dosing is 10-15 
mg/kg as loading over a period of 5-10 days followed 2-5 mg/kg as once a day dose. IV dosing 
is safe17 and is recommended in a 1-5 mg/kg/dose over a period of 1-2 hours slowly followed by 
a maintenance infusion of 5-15 mcg/kg/min. Higher loading doses may be required in some 
cases. Side effects may be significant especially with long term administration and include 
hypothyroidism,  skin photosensitivity,  chemical hepatitis, pulmonary fibrosis and corneal 
microdeposits that are reversible. Regular thyroid function, liver function and pulmonary 
function tests are essential  to  avoid  undesirable  effects  and  may  need  reducing  the  dose  or 
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supplemental thyroxine. Cardiac side effects include sinus and AV node dysfunction and rarely 
proarrhythmia   (such   as   torsades).                                                                        
Sotalol: It is a non-selective betablocker with all above mentioned class III effects. Its use in 
postoperative chronic management of several arrhythmias such as atrial flutter, EAT and VT is 
well described. Oral absorption is good and transplacental passage of the drug has been used in 
treating fetal arrhythmias. Oral dosing is 90-200 mg/m2 in 3 divided doses. Side effects include 
bradycardia,   hypotension   and   prolongation   of   QTc   with   a   risk   of   torsades18.  
Class   IV   drugs                                                                        
            These bock the Ca channels and have a predominant effect on the sinus and AV node.   
Verapamil: It is effective in depressing enhanced automaticity and is a potent alpha adrenergic 
blocker. The Ca channel blocking properties are more prominent at faster heart rates. It has a 
large volume of distribution and is metabolized in the liver. It is mainly used in re-entry SVTs, 
hypertrophic cardiomyopathy and some left sided VTs. Oral dosing is between 4-15mg/kg/day in 
3-4 divided doses. Sustained release preparations are available and are administered once or 
twice daily. Side effects include headaches, rashes, constipation, bradycardia and postural 
hypotension. Use of the IV preparation in infants can result in asystole and cardiovascular 
collapse19  and   hence   is   contraindicated.                                                                  
Diltiazem: It blocks the inward Ca channel activity and has predominant effect on the sinus and 
AV node. It has been used predominantly in control of hypertension and acute treatment of 
SVT20. Its use is similar to verapamil and dosing recommendations are 0.5-2 mg/kg/day in 2-3 
divided doses. Side effects include bradycardia and postural hypotension.                       
Other   agents                                                                                  
Adenosine:  It is an endogenous purigenic agent that increases K channel conductance and 
depresses inward Ca current resulting in transient AV block. It has wide therapeutic and 
diagnostic use in emergency room management of re-entry (Figure 3) and automatic SVTs such 
as ectopic atrial tachycardia (Figure 4) and some forms of adenosine sensitive VTs. IV dosing is 
150-300 mcg/kg given rapidly because of its short half life (few seconds)21. Side effects include 
flushing,   hypotension,   chest   pain   (transient   coronary   spasm),   bronchospasm   and   atrial 
fibrillation.
Digoxin: This has several mechanisms of action. The direct effects include binding to Na-K 
ATPase complex and thus inhibiting Na channel. The inotropic response is due to Ca loading 
from higher intracellular Na concentration from the enhancement of Na-Ca pump. It also 
increases parasympathetic output22 and inhibits norepinephrine release. The drug is excreted in 
the urine unchanged and also crosses the placenta (hence its use as drug of choice in fetal 
arrhythmias).  Oral dosing is 30-50 mcg/kg loading over 24 hrs in divided doses followed by 
7-10 mcg/kg per day. IV dosing is two-thirds of oral dosing. Side effects include nausea, GI and 
visual disturbance. Cardiovascular effects of digoxin toxicity include bradycardia, AV block and 
ventricular   arrhythmias.   Electrolyte   and   renal   abnormalities   (especially   hypokalemia   and 
hypomagnesemia) potentiate digoxin toxicity.
Conclusion
            In summary, antiarrhythmic drug therapy in children is very effective in situations where 
ablation is not preferred. Side-effects of different drugs and combinations need to be taken into 
consideration and monitored during treatment. 
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Figure 3:  Effect of Adenosine on re-entry SVT. (Lead II and HRA tracings) Upper panel shows response in 
AVNRT. Termination of tachycardia is seen after a ventricular response. Lower panel shows the response in ORT 
where the tachycardia terminates after an atrial response. (AVNRT- AV node re-entry tachycardia; ORT-
orthodromic re-entry SVT, NSR- normal sinus rhythm, HRA- high right atrium).
Figure 4: Effect of Adenosine in Ectopic atrial tachycardia. With blocking of the AV node the ventricular response 
is slowed but tachycardia continues. Response lasts less than 30 seconds.
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